活动平台与固定平台全踝关节置换的临床比较:非设计中心236踝病例系列
本研究在单一非设计中心连续比较活动平台(Zenith)与固定平台(Infinity)全踝关节置换的临床结局和假体生存率。固定平台组5年假体生存率显著优于活动平台组,翻修率更低;两组患者报告结局均改善,但差异无统计学意义。
要点
- 固定平台(Infinity)5年假体生存率98.7%,显著高于活动平台(Zenith)的91.3%。
- 活动平台组翻修率9.3%(11/118),固定平台组0.8%(1/118),翻修主因均为无菌性松动。
- 两组PROMs(MOXFQ和VAS疼痛)均改善,但组间差异无统计学意义。
核心结论
- 固定平台(Infinity)全踝关节置换的假体生存率显著优于活动平台(Zenith)。
- 两组患者报告结局均改善,但差异无统计学意义。
研究设计与样本
- 单中心非设计者病例系列,连续纳入活动平台(Zenith)118踝(2010年12月至2016年5月)和固定平台(Infinity)118踝(2017年9月至2019年11月),共230例患者。
- 收集人口学、临床和患者报告结局指标(PROMs),终点为需翻修一个或多个组件的假体失败,采用Kaplan-Meier生存分析。
主要发现
- 随访期间32例患者(36踝)死亡,均未需翻修;存活198例(200踝;Zenith 93踝,Infinity 107踝)中,Zenith组平均随访9.1年(6.0至13.1),Infinity组5.0年(3.8至7.0)。
- Zenith组11踝(9.3%)需翻修,Infinity组1踝(0.8%)需翻修;Zenith组平均失败时间3.2年(0.4至10.5),Infinity组唯一翻修患者为4.1年。
- 5年假体生存率(以翻修为终点):Zenith组91.3%(95%CI 96.9至85.6),Infinity组98.7%(95%CI 99.5至97.8)。
- MOXFQ评分:Zenith组从85.0(SD 12.6)改善至32.8(SD 22.9),Infinity组从76.2(SD 14.5)改善至21.7(SD 22.7);VAS疼痛评分:Zenith组从7.0(SD 1.4)改善至3.2(SD 1.7),Infinity组从6.9(SD 1.6)改善至2.7(SD 2.0)。
- 两组翻修最常见指征均为无菌性松动。
关键数值与推荐
- 5年假体生存率:活动平台(Zenith)91.3%(95%CI 96.9至85.6),固定平台(Infinity)98.7%(95%CI 99.5至97.8)。
- 翻修率:活动平台组9.3%(11/118踝),固定平台组0.8%(1/118踝)。
临床怎么用
- 在非设计中心环境中,固定平台全踝关节置换可能提供更优的中期假体生存率。
- 选择活动平台假体时需向患者告知相对较高的翻修风险。
局限性
- 非随机对照设计,两组手术时期不同,随访时间存在差异(活动平台组平均9.1年 vs 固定平台组5.0年)。
- 来自单一非设计中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to compare the clinical outcomes and implant survival of mobile-bearing (Zenith) and fixed-bearing (Infinity) total ankle arthroplasties (TAAs) in two consecutive demographically similar groups of patients, from a single, non-designer centre. METHODS: Between December 2010 and May 2016, 118 consecutive mobile-bearing TAAs (Zenith), and between September 2017 and November 2019, 118 consecutive fixed-bearing TAAs (Infinity), were implanted in a total cohort of 230 patients. Demographic, clinical, and patient-reported outcome measures (PROMs) were collected. The endpoint of the study was failure of the implant requiring revision of one or more of the components. Kaplan-Meier survival tables were generated. RESULTS: Demographic data were similar in both groups. A total of 32 patients (36 TAAs) died during the follow-up period, but none required revision. Of the surviving 198 patients (200 TAAs; 93 Zenith, 107 Infinity), the mean follow-up was 9.1 years (6.0 to 13.1) in the Zenith and 5.0 years (3.8 to 7.0) in the Infinity group. A total of 11 TAAs (9.3%) in the Zenith group and one (0.8%) in the Infinity group required revision. The mean time to failure was 3.2 years (0.4 to 10.5) in the Zenith group and 4.1 years for the one patient requiring revision in the Infinity group. Implant survival at five years, using revision as an endpoint, was 91.3% (95% CI 96.9 to 85.6) for Zenith and 98.7% (95% CI 99.5 to 97.8) for Infinity. There was an improvement in the mean Manchester-Oxford Foot and Ankle Questionnaire score from 85.0 (SD 12.6) to 32.8 (SD 22.9) in the Zenith group and 76.2 (SD 14.5) to 21.7 (SD 22.7) in the Infinity group, and in the mean visual analogue scale scores for pain from 7.0 (SD 1.4) to 3.2 (SD 1.7) in the Zenith group and 6.9 (SD 1.6) to 2.7 (SD 2.0) in the Infinity group. The most common indication for revision was aseptic loosening in both groups. CONCLUSION: These findings showed significantly better survival for the fixed-bearing (Infinity) compared with the mobile-bearing (Zenith) TAAs. While the Infinity group had better PROM scores, the difference was not statistically significant.
引用
- Clough TM, Bitar S. Clinical comparison of mobile-bearing versus fixed-bearing total ankle arthroplasty : case series of 236 ankles from a non-designer centre. Bone Joint J. 2026. PMID: 41916543. doi:10.1302/0301-620X.108B4.BJJ-2025-0315.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。